top of page
  • Recruiting
    • Dec 19, 2019

NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2

Updated: Oct 3, 2022

CARTITUDE-2

Ciltacabtagene Autoleuce

CARTITUDE-2

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.


Sponsor

Janssen Research & Development, LLC


Legend Biotech

 

ClinicalTrials.gov Identifier: NCT04133636

Official Title: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma

First Posted : October 21, 2019

Click here for ClinicalTrials.gov

 

CART - BCMA : National Cancer Institute